Rosiglitazone Attenuates Cerebral Vasospasm and Provides Neuroprotection in an Experimental Rat Model of Subarachnoid Hemorrhage

2014 ◽  
Vol 21 (2) ◽  
pp. 316-331 ◽  
Author(s):  
Bo-Feng Lin ◽  
Chan-Yang Kuo ◽  
Li-Li Wen ◽  
Chun-Mei Chen ◽  
Ya-Feng Chang ◽  
...  
Neurosurgery ◽  
2017 ◽  
Vol 80 (5) ◽  
pp. 809-815 ◽  
Author(s):  
Yu-Hua Huang ◽  
Chia-Li Chung ◽  
Hung-Pei Tsai ◽  
Shu-Chuan Wu ◽  
Chih-Zen Chang ◽  
...  

2009 ◽  
Vol 110 (5) ◽  
pp. 1015-1020 ◽  
Author(s):  
Ibrahim Omeis ◽  
Weiliam Chen ◽  
Meena Jhanwar-Uniyal ◽  
Renato Rozental ◽  
Raj Murali ◽  
...  

Object One mechanism that contributes to cerebral vasospasm is the impairment of potassium channels in vascular smooth muscles. Adenosine triphosphate–sensitive potassium channel openers (PCOs) appear to be particularly effective for dilating cerebral arteries in experimental models of subarachnoid hemorrhage (SAH). A mode of safe administration that provides timed release of PCO drugs is still a subject of investigation. The authors tested the efficacy of locally delivered intrathecal cromakalim, a PCO, incorporated into a controlled-release system to prevent cerebral vasospasm in a rat model of SAH. Methods Cromakalim was coupled to a viscous carrier, hyaluronan, 15% by weight. In vitro release kinetics studies showed a steady release of cromakalim over days. Fifty adult male Sprague-Dawley rats weighing 350–400 g each were divided into 10 groups and treated with various doses of cromakalim or cromakalim/hyaluronan in a rat double SAH model. Treatment was started 30 minutes after the second SAH induction. Animals were killed 3 days after treatment, and the basilar arteries were processed for morphometric measurements and histological analysis. Results Controlled release of cromakalim from the cromakalim/hyaluronan implant at a dose of 0.055 mg/kg significantly increased lumen patency in a dose-dependent manner up to 94 ± 8% (mean ± standard error of the mean) of the basilar arteries of the sham group compared with the empty polymer group (p = 0.006). Results in the empty polymer group were not different from those in the SAH-only group, with a lumen patency of 65 ± 12%. Lumen patencies of the cromakalim-only groups did not differ in statistical significance at low (64 ± 9%) or high (66 ± 7%) doses compared to the SAH-only group. Conclusions Treatment of SAH with a controlled-release cromakalim/hyaluronan implant prevented experimental cerebral vasospasm in this rat double hemorrhage model; this inhibition was dose-dependent. The authors' results confirm that sustained delivery of cromakalim perivascularly to cerebral vessels could be an effective therapeutic strategy in the treatment of cerebral vasospasm after SAH.


Sign in / Sign up

Export Citation Format

Share Document